The shares of nanocap biotech Regen BioPharma (OTCPK:RGBP) surged 21% on Wednesday to reach the highest level since May after the company announced the submission of a U.S. patent application related to a mRNA cancer immunotherapeutic vaccine.
The provisional patent application covers the use of dendritic cell technologies to enhance the company’s patented survivin mRNA cancer immunotherapeutic vaccine, Regen (OTCPK:RGBP) said.
"The currently filed application discloses means of significantly increasing efficacy by combining modified-mRNA with unique cellular immunotherapy as well as adjuvant approaches,” Chief Executive Dr. David Koos remarked.
In 2021, the U.S. Patent and Trademark Office awarded the patent # 11,090,332 for Regen (OTCPK:RGBP), covering the IP rights related to the composition of matter of survivin modified-mRNA useful for training the immune system to destroy cancer.
Read more about Regen’s (OTCPK:RGBP) intellectual property portfolio.
News 
Market Data 
Discover 
